טוען...
Peginesatide for the treatment of anemia due to chronic kidney disease – an unfulfilled promise
INTRODUCTION: The introduction of recombinant human erythropoietin revolutionized the management of anemia in patients with chronic kidney disease (CKD). In order to circumvent costly recombinant DNA technology, synthetic chemistry techniques were used to manufacture peginesatide, a synthetic peptid...
שמור ב:
| הוצא לאור ב: | Expert Opin Drug Saf |
|---|---|
| Main Authors: | , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
2016
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5286458/ https://ncbi.nlm.nih.gov/pubmed/27551882 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/14740338.2016.1218467 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|